Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2013 - 2017)
Regeneron Pharmaceuticals (REGN) posted quarterly Long-Term Debt Repayments of $57.0 million for Q1 2017, up 3177.75% year-over-year from $1.7 million in Q1 2016, and up 182.88% quarter-over-quarter from $20.2 million in Q4 2016.
Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2013 - 2017) Analysis & Trends
Regeneron Pharmaceuticals' Long-Term Debt Repayments history runs 5 years deep, the most recent figure standing at $57.0 million for Q1 2017.
- In Q1 2017, Long-Term Debt Repayments rose 3177.75% year-over-year to $57.0 million; the TTM figure through Dec 2017 stood at $57.0 million (up 73.78% YoY), while the FY2017 annual figure was $57.0 million, up 73.78% from the prior year.
- Long-Term Debt Repayments for Q1 2017 stood at $57.0 million, up from $20.2 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $159.5 million in Q4 2014, with the low at -$2.0 million in Q4 2013.
- The 5-year median for Long-Term Debt Repayments is $18.4 million (2015), against an average of $39.6 million.
- The sharpest annual moves came in 2014 and 2016: Long-Term Debt Repayments surged 7981.13% in 2014, then sank 91.43% in 2016.
- Regeneron Pharmaceuticals' Long-Term Debt Repayments stood at -$2.0 million in 2013, then soared by 7981.13% to $159.5 million in 2014, then sank by 87.15% to $20.5 million in 2015, then retreated by 1.67% to $20.2 million in 2016, then soared by 182.88% to $57.0 million in 2017.
- Business Quant data shows REGN's Long-Term Debt Repayments at $57.0 million in Q1 2017, $20.2 million in Q4 2016, and $10.9 million in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 17.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 37.08 Mn |
| Dec 31, 2017 | 37.08 Mn |
| Jun 30, 2017 | -37.08 Mn |
| Jun 30, 2017 | -37.08 Mn |
| Mar 31, 2017 | 57.00 Mn |
| Mar 31, 2017 | 57.00 Mn |
| Dec 31, 2016 | 250,000.00 |
| Dec 31, 2016 | 250,000.00 |
| Jun 30, 2016 | 12.65 Mn |
| Jun 30, 2016 | 12.65 Mn |
| Dec 31, 2015 | 140.06 Mn |
| Dec 31, 2015 | 140.06 Mn |
| Sep 30, 2015 | -117.60 Mn |
| Sep 30, 2015 | -117.60 Mn |
| Jun 30, 2015 | 137.26 Mn |
| Jun 30, 2015 | 137.26 Mn |
| Mar 31, 2015 | 6.74 Mn |
| Mar 31, 2015 | 6.74 Mn |
| Dec 31, 2014 | -62.22 Mn |
| Dec 31, 2014 | -62.22 Mn |